A poorly circumscribed morphologic variant of rhabdomyosarcoma. It is characterized by the presence of primitive skeletal muscle differentiation in any stage of myogenesis.
Comprehensive, easy-to-understand information about this condition
How we create this content →The documentation for embryonal rhabdomyosarcoma is limited primarily due to its rarity, which affects fewer than 1 in 100,000 individuals. This rarity results in fewer systematic clinical studies and comprehensive data collection, making it challenging to characterize the condition fully. Additionally, the genetic basis was only recently identified, and ongoing clinical characterization is still needed.
To navigate care for embryonal rhabdomyosarcoma, consider consulting a pediatric oncologist who specializes in soft tissue sarcomas. Genetic counseling may also be beneficial to understand the implications of the SLC67A1 gene variant for you and your family. While no patient organizations are currently identified for this condition, you can find support and resources through the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov. Additionally, participating in clinical trials may provide access to cutting-edge therapies and contribute to the understanding of this rare condition.
Currently, there are 51 active clinical trials investigating various aspects of embryonal rhabdomyosarcoma. These trials may explore new treatment options and management strategies. For more information about these trials, you can visit ClinicalTrials.gov and search for embryonal rhabdomyosarcoma: https://clinicaltrials.gov/search?cond=embryonal%20rhabdomyosarcoma.
Actionable guidance for navigating care for embryonal rhabdomyosarcoma
To navigate care for embryonal rhabdomyosarcoma, consider consulting a pediatric oncologist who specializes in soft tissue sarcomas. Genetic counseling may also be beneficial to understand the implications of the SLC67A1 gene variant for you and your family. While no patient organizations are currently identified for this condition, you can find support and resources through the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov. Additionally, participating in clinical trials may provide access to cutting-edge therapies and contribute to the understanding of this rare condition.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The documentation for embryonal rhabdomyosarcoma is limited primarily due to its rarity, which affects fewer than 1 in 100,000 individuals. This rarity results in fewer systematic clinical studies and comprehensive data collection, making it challenging to characterize the condition fully. Additionally, the genetic basis was only recently identified, and ongoing clinical characterization is still needed.
To navigate care for embryonal rhabdomyosarcoma, consider consulting a pediatric oncologist who specializes in soft tissue sarcomas. Genetic counseling may also be beneficial to understand the implications of the SLC67A1 gene variant for you and your family. While no patient organizations are currently identified for this condition, you can find support and resources through the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov. Additionally, participating in clinical trials may provide access to cutting-edge therapies and contribute to the understanding of this rare condition.
Currently, there are 51 active clinical trials investigating various aspects of embryonal rhabdomyosarcoma. These trials may explore new treatment options and management strategies. For more information about these trials, you can visit ClinicalTrials.gov and search for embryonal rhabdomyosarcoma: https://clinicaltrials.gov/search?cond=embryonal%20rhabdomyosarcoma.
Actionable guidance for navigating care for embryonal rhabdomyosarcoma
To navigate care for embryonal rhabdomyosarcoma, consider consulting a pediatric oncologist who specializes in soft tissue sarcomas. Genetic counseling may also be beneficial to understand the implications of the SLC67A1 gene variant for you and your family. While no patient organizations are currently identified for this condition, you can find support and resources through the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov. Additionally, participating in clinical trials may provide access to cutting-edge therapies and contribute to the understanding of this rare condition.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The documentation for embryonal rhabdomyosarcoma is limited primarily due to its rarity, which affects fewer than 1 in 100,000 individuals. This rarity results in fewer systematic clinical studies and comprehensive data collection, making it challenging to characterize the condition fully. Additionally, the genetic basis was only recently identified, and ongoing clinical characterization is still needed.
To navigate care for embryonal rhabdomyosarcoma, consider consulting a pediatric oncologist who specializes in soft tissue sarcomas. Genetic counseling may also be beneficial to understand the implications of the SLC67A1 gene variant for you and your family. While no patient organizations are currently identified for this condition, you can find support and resources through the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov. Additionally, participating in clinical trials may provide access to cutting-edge therapies and contribute to the understanding of this rare condition.
Currently, there are 51 active clinical trials investigating various aspects of embryonal rhabdomyosarcoma. These trials may explore new treatment options and management strategies. For more information about these trials, you can visit ClinicalTrials.gov and search for embryonal rhabdomyosarcoma: https://clinicaltrials.gov/search?cond=embryonal%20rhabdomyosarcoma.
Actionable guidance for navigating care for embryonal rhabdomyosarcoma
To navigate care for embryonal rhabdomyosarcoma, consider consulting a pediatric oncologist who specializes in soft tissue sarcomas. Genetic counseling may also be beneficial to understand the implications of the SLC67A1 gene variant for you and your family. While no patient organizations are currently identified for this condition, you can find support and resources through the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov. Additionally, participating in clinical trials may provide access to cutting-edge therapies and contribute to the understanding of this rare condition.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Inheritance patterns describe how genetic conditions are passed from parents to children.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 31, 2026
Consider asking your healthcare providers these condition-specific questions
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.